Appointment of Joint Corporate Broker
In brief · summary, not quotable
No summary for this filing – the full text is below.
Full announcement
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, today announces the appointment of Stifel Nicolaus Europe Limited ("Stifel") as joint corporate broker with immediate effect.
Liberum will continue as Nominated Adviser and Joint Corporate Broker to the Company.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.